All In Biotech

Drug Trial Radar · NCT06846541

Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis

An Extension Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Long-term Safety, Efficacy, and Durability of Response to ESK-001

Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 1,680 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,680

Planned (sponsor's estimate)

Start

Jan 8, 2025

Primary completion

Nov 2028

Study completion Nov 2028

Sponsor

Lead sponsor
Alumis IncIndustry
Sponsor type
Industry
First posted
Feb 26, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of the ESK-001-018 long term extension is to evaluate the safety and efficacy of ESK-001 over time. The scientific questions it aims to answer are: * How safe is taking ESK-001 long-term in people with moderate to severe plaque psoriasis? * Does taking ESK-001 long-term reduce the severity of people's plaque psoriasis? Patients will enter the long-term extension study following completion of one of the parent studies (ESK-001-016 or ESK-001-017) and will receive open-label ESK-001 twice daily for 24 weeks. After 24 weeks, the first 200 patients meeting at least PASI-75 clinical response will be randomly assigned to receive ESK-001 or placebo. At any point during this time, the patients losing the initial clinical response may return to the open-label ESK-001 treatment. Patients who complete Week 48 will return to open-label ESK-001 treatment and they will receive ESK-001 until the end of the study or discontinuation. All the remaining patients not meeting the entry criteria for the randomized withdrawal phase will continue to receive open-label ESK-001 for the remainder of the study. Patients taking part in the study must be men or women aged at least 18 years old and have completed a previous (parent) study of ESK-001 in moderate to severe plaque psoriasis. Patients must consent and agree to: * ensure drug daily compliance until end of study or discontinuation. * visit the clinic for checkups and assessments. * provide blood and urine samples.

Conditions

  • Plaque Psoriasis
  • Psoriasis (PsO)
  • Psoriasis
  • Moderate Psoriasis
  • Severe Psoriasis

Interventions

  • Open-Label EnvudeucitinibDrug

    Open-Label ESK-001

  • Blinded EnvudeucitinibDrug

    Blinded ESK-001 during Randomized Treatment Withdrawal Period

  • PlaceboDrug

    Placebo during Randomized Treatment Withdrawal Period

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To assess the long-term safety and tolerability of ESK-001 throughout the duration of the studyTime frame: Approximately 4 years

Locations

268 sites in 16 countries. Site status is shown where the registry gives one.

  • Total Dermatology

    Birmingham, Alabama

  • Chandler Clinical Trials

    Chandler, Arizona

  • Alliance Dermatology

    Pheonix, Arizona

  • Scottsdale Clinical Trials

    Scottsdale, Arizona

  • Noble Clinical Research

    Tucson, Arizona

  • Northwest AR Clinical Trials Center PLLC

    Rogers, Arkansas

  • Zenith Research Inc.

    Beverly Hills, California

  • Exalt Clinical Research Inc

    Chula Vista, California

  • California Dermatology and Clinical Research Institute

    Encinitas, California

  • Raoof MD

    Encino, California

  • First OC Dermatology Research Inc

    Fountain Valley, California

  • Marvel Clinical Research LLC

    Huntington Beach, California

  • Long Beach Research Institute

    Long Beach, California

  • Olive View UCLA Education and Research Institute

    Los Angeles, California

  • Dermatology Research Associates

    Los Angeles, California

  • Wallace Medical Group Inc

    Los Angeles, California

  • Northridge Clinical Trials

    Northridge, California

  • Pasadena Clinical Trials

    Pasadena, California

  • Empire Clinical Research Pomona

    Pomona, California

  • Integrative Skin Science and Research

    Sacramento, California

  • Therapeutics Clinical Research

    San Diego, California

  • Southern California Clinical Research

    Santa Ana, California

  • Clinical Science Institute Dermatology Institute

    Santa Monica, California

  • Unison Clinical Trials

    Sherman Oaks, California

  • California Dermatology Institute Thousand Oaks

    Thousand Oaks, California

  • Sunwise Clinical Research LLC

    Walnut Creek, California

  • Clearlyderm Dermatology West Boca Raton

    Boca Raton, Florida

  • Driven Clinical Research

    Coral Gables, Florida

  • FXM Clinical Research Ft. Lauderdale LLC

    Fort Lauderdale, Florida

  • Direct Helpers Research Center

    Hialeah, Florida

  • Jacksonville Center for Clinical Research

    Jacksonville, Florida

  • Glick Skin Institute

    Margate, Florida

  • AppleMed Research Group

    Miami, Florida

  • FAX Pharma Clinical Research Inc

    Miami, Florida

  • FXM Clinical Research Miami LLC

    Miami, Florida

  • Las Mercedes Medical Research

    Miami, Florida

  • Procare Research Center

    Miami Gardens, Florida

  • San Marcus Research Clinic Inc - Miami

    Miami Lakes, Florida

  • Savin Medical Group LLC

    Miami Lakes, Florida

  • FXM Clinical Research Miramar LLC

    Miramar, Florida

Showing 40 of 268 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.